James Watson’s Personal Genome Published in Nature


By Kevin Davies

April 16, 2008 | Fifty-five years after James Watson co-authored the most famous paper in Nature magazine’s history -- the discovery of the DNA double helix with Francis Crick -- his genome sequence is also gracing the pages of the famous scientific journal.

Following months of extensive review and revision, Nature finally publishes the paper reporting the Watson’s personal genome, or “Project Jim” as it was known, this week. The sequencing itself was performed by 454 Life Sciences, part of Roche, led by its founder and past chairman, Jonathan Rothberg. The bioinformatics analysis was handled by scientists at the Baylor College of Medicine genome center, led by Director Richard Gibbs and bioinformatician David Wheeler.

Watson’s sequence becomes the second full human genome sequence to be published, following the publication of Craig Venter’s sequence last year. But whereas Venter’s genome took years of work using traditional Applied Biosystems sequencing instruments, costing a reputed $70 million, the Watson genome was sequenced in a couple of months early last year using the 454 GS FLX pyrosequencing instruments. 454 estimates the final cost to be between $1-2 million. “This is the first [human] genome sequenced by next-generation technologies,” the authors emphasize.

 Jonathan Rothberg, James Watson 
James Watson (left) receives a digital copy of his genome sequence from Jonathan Rothberg in May 2007.

 

Last May, Rothberg presented a digital copy of the raw sequence on a portable hard drive to Watson in a ceremony at Baylor College of Medicine. (Rothberg is no longer affiliated with 454/Roche.) Watson’s genome assembly – with the exception of one Alzheimer’s associated gene (APOE on chromosome 19) that was redacted at Watson’s behest -- has been publicly annotated and presented by Lincoln Stein at Cold Spring Harbor Laboratory.

The Nature paper details the highlights of Watson’s genome analysis. All told, more than 93 million DNA sequence traces, averaging about 250 bases in length, were assembled to produce the final sequence. Of those, more than 1 million did not correspond to the reference genome sequence, indicating there is much more genomic variation between individuals than previously thought. The 454 team also points out that its amplification procedure dispenses with bacteria, and thus leads to more even representation of the full genome.

The final tally of 24.5 billion bases provides more than seven-fold coverage of the genome. Wheeler and colleagues documented more than 3.3 million single nucleotide polymorphisms (SNPs), of which more than 10,000 alter the primary amino-acid sequence of proteins.

The paper contains a one-page box written by Baylor bioethicist Amy McGuire on the ethical considerations in handling and communicating this genetic and medical information with Dr. Watson.

LSWebcast logoEditor’s Note: Last year, Kevin Davies interviewed lead author David Wheeler on the sequencing of the Watson genome. See the full interview here.

Further Reading: Wheeler, D. et al. “The complete genome of an individual by massively parallel DNA sequencing.” Nature 452; April 17, 2008. doi:10.1038/nature06884

 

 

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

thomson reuters image
Biomarkers: An Indispensible Addition to the Drug Development Toolkit
Examining the Potential of Biomarkers
Sponsored by Thomson Reuters

Biomarkers are becoming an essential part of clinical development. In this white paper, Thomson Reuters provides insight from experts in industry and academia, and explores the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents.

Discover the potential of biomarkers to:

  • Improve decision making
  • Accelerate drug development
  • Reduce development costs


BlueArc_Scientific Data
Scientific Data Lifecycle Management: Preparing for Storage in an Uncertain Future
Sponsored by BlueArc

Managing vast and overwhelming streams of gene sequencing data today requires ultra-high performance systems and processes. With continued rapid advancement and improvements in gene sequencing, expect tomorrow’s instruments to output quantities of genomic information that will dwarf current levels. Help your organization maintain data control and prepare for the future of sequencing through this informative paper that discusses:

  • The information technology challenges of gene sequencing
  • “Intelligent” methods for data management and customization
  • System survival tips... Deciding what data to keep or delete
  • New tools to keep scientists ahead of impending data torrents


SAS Managed image
Managed Innovation, Assured Compliance
Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
Sponsored by SAS
Get better products to market faster. Download this white paper to discover the top ten challenges facing life science executives and how to overcome them. See how SAS Drug Development transforms clinical data into true innovation.


Life Science Webcasts & Podcasts

Presented by Trade Commission of Spain

Spain Biotech: An Engine for Economic Change 

TCS podcastDiscover how Spain is focusing on biotechnology to be an engine for economic change through gradual internationalization, development and technology transfer.

Regional governments are actively investing in public and private biology research and promoting the creation of knowledge-based companies. Spain’s human capital combined with aggressive investment in biotech research and infrastructure has led to the creation of bio-clusters.

Today, there are nearly 700 Spanish companies engaged in biotechnology, with almost 50 percent growth in funding devoted to research. In fact, spending on internal R & D in biotechnology has grown 46 percent and is close to 300 million Euros.

Access the podcast 

 



More Podcasts

Job Openings

saic_logo

MANAGER, SCIENTIFIC COMPUTING & PROGRAMMING
(Bioinformatics Manager)
SAIC-Frederick, Inc has an exciting opportunity for a Manager, Scientific Computing & Programming - Core Genoytyping Facility in Gaithersburg, Maryland.  In this role, you will lead the Bioinformatics & Analysis Group.
Master’s or equivalent required.  PhD preferred. Six years experience in development of scientific programs in high-performance computing environment including five years supporting scientific research in computational chemistry, biology, or genetics, & two years supervisory experience.  View complete job posting & apply: www.saic-frederick.com. Position #146945.

For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.